A detailed history of Stifel Financial Corp transactions in Axsome Therapeutics, Inc. stock. As of the latest transaction made, Stifel Financial Corp holds 5,507 shares of AXSM stock, worth $769,272. This represents 0.0% of its overall portfolio holdings.

Number of Shares
5,507
Previous 4,322 27.42%
Holding current value
$769,272
Previous $451,000 48.12%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Nov 12, 2025

BUY
$100.39 - $129.29 $118,962 - $153,208
1,185 Added 27.42%
5,507 $668,000
Q2 2025

Aug 14, 2025

BUY
$95.65 - $116.49 $413,399 - $503,469
4,322 New
4,322 $451,000
Q3 2021

Nov 15, 2021

SELL
$19.91 - $68.26 $8.1 Million - $27.8 Million
-406,935 Closed
0 $0
Q2 2021

Aug 13, 2021

BUY
$50.63 - $73.5 $6,885 - $9,996
136 Added 0.03%
406,935 $27.5 Million
Q1 2021

May 14, 2021

BUY
$55.91 - $81.44 $42,994 - $62,627
769 Added 0.19%
406,799 $23 Million
Q4 2020

Feb 12, 2021

SELL
$66.31 - $86.52 $35,674 - $46,547
-538 Reduced 0.13%
406,030 $33.1 Million
Q3 2020

Nov 16, 2020

SELL
$68.34 - $85.84 $2,050 - $2,575
-30 Reduced 0.01%
406,568 $29 Million
Q2 2020

Aug 14, 2020

BUY
$49.87 - $98.69 $122,331 - $242,086
2,453 Added 0.61%
406,598 $33.5 Million
Q3 2019

Nov 13, 2019

SELL
$20.24 - $29.16 $7,569 - $10,905
-374 Reduced 0.09%
404,145 $8.18 Million
Q2 2019

Aug 14, 2019

BUY
$13.46 - $25.75 $5,034 - $9,630
374 Added 0.09%
404,519 $10.4 Million
Q1 2018

May 11, 2018

SELL
$2.35 - $5.6 $26,164 - $62,350
-11,134 Reduced 2.68%
404,145 $990,000
Q3 2017

Nov 13, 2017

BUY
$4.65 - $6.1 $1.93 Million - $2.53 Million
415,279
415,279 $0

Others Institutions Holding AXSM

About Axsome Therapeutics, Inc.


  • Ticker AXSM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 42,878,000
  • Market Cap $5.99B
  • Description
  • Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinic...
More about AXSM
Track This Portfolio

Track Stifel Financial Corp Portfolio

Follow Stifel Financial Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Stifel Financial Corp, based on Form 13F filings with the SEC.

News

Stay updated on Stifel Financial Corp with notifications on news.